07Nov/13

Monoclonal Antibodies Market in Breast Cancer with 2019 Forecasts in New … – PR Web (press release)

Monoclonal Antibodies Market in Breast Cancer with 2019 Forecasts in New
PR Web (press release)
RnRMarketResearch.com adds Latest Report on “Monoclonal Antibodies Market in Breast Cancer to 2019 – Strong Uptake of Novel HER-2 Targeted Therapies to Drive Robust Growth” to its store. Share on Twitter Share on Facebook Share on Google+ 
Breast Cancer mAbs Market Worth 10.6B by 2019 in 8 CountriesMENAFN.COM

all 2 news articles »

07Nov/13

Research and Markets: Therapy Class Overview : Rituximab Biosimilar … – Fort Mills Times

Research and Markets: Therapy Class Overview : Rituximab Biosimilar
Fort Mills Times
Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson’s Remicade, which is approved for RA, Crohn’s disease and several

and more »